Arresting Early Childhood Caries With a Silver Diamine Fluoride Gel
Launched by THE UNIVERSITY OF HONG KONG · Jan 26, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effective a special gel called silver diamine fluoride (SDF) is at stopping early childhood cavities. The trial aims to find out if a 38% SDF gel works just as well as a 38% SDF solution when applied to young children's teeth every six months over a two-and-a-half-year period. The goal is to help preschool children with at least one cavity and see if this treatment can help prevent further tooth decay.
To participate in this study, children must be generally healthy and have at least one tooth with a cavity. However, kids who have severe dental problems, are uncooperative, or are undergoing other dental treatments won’t be eligible. Participants will receive the SDF treatment during their visits, and all children, regardless of gender, between the ages of 3 and 5 years old are welcome to join. This trial is currently looking for participants, and it's an opportunity for families to contribute to research that could improve dental care for young children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • generally healthy, have at least one tooth with cavitated dentine carious lesion
- Exclusion Criteria:
- • uncooperative and difficult to manage, with severe forms of hypoplasia of fluorosis or other oral diseases, wearing orthodontic devices or under dental treatment, have major systemic diseases, or are on long-term medication
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , China
Patients applied
Trial Officials
Chun Hung Chu, Ph.D
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported